Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of
a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) and
is required for the establishment of new blood vessels during tumor growth, a process known
as angiogenesis.